The Use of Antiinflammatory Therapy and Macrolides in Bronchiectasis

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 371-380

  Feldman, Charles ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Anti inflammatory; Corticosteroids; Macrolides; Nonsteroidal antiinflammatory agents

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE PROPIONATE; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR STIMULATING AGENT; MACROLIDE; METHYLXANTHINE; PLACEBO; ROXITHROMYCIN;

ANTIINFLAMMATORY ACTIVITY; BRONCHIECTASIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; IMMUNOMODULATION; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG FUNCTION; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SPUTUM CULTURE; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; HUMANS; MACROLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84861545872     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.02.001     Document Type: Review

References (65)

1. King P. Pathogenesis of bronchiectasis. Paediatr Respir Rev 2011, 12:104-110.
2. Stafler P., Carr S.B. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed 2010, 95:73-82.
3. Wilson R. Bronchiectasis. Respiratory infections 2001, 347-359. Lippincott Williams & Wilkins, Philadelphia. 2nd edition. M.S. Niederman, G.A. Sarosi (Eds.).
4. Cole P.J. Bronchiectasis. Respiratory medicine 1995, 1286-1317. WB Saunders, London. 2nd edition. R.A. Brewis, B. Corrin, D.M. Geddes (Eds.).
5. Tsang K.W., Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009, 14:637-650.
6. Kharitonov S.A., Wells A.U., O'Connor B.J., et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995, 151(6):1889-1893.
7. Horvath I., Loukides S., Wodehouse T., et al. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax 1998, 53(10):867-870.
8. Loukides S., Horvath I., Wodehouse T., et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med 1998, 158(3):991-994.
9. Gaga M., Bentley A.M., Humbert M., et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998, 53(8):685-691.
10. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?. Drugs 2007, 67(7):965-974.
11. Loebinger M.R., Wilson R. Pharmacotherapy for bronchiectasis. Expert Opin Pharmacother 2007, 8(18):3183-3193.
12. O'Donnell A.E. Bronchiectasis. Chest 2008, 134:815-823.
13. Prasad M., Tino G. Bronchiectasis, part 2: management. J Respir Dis 2008, 29(1):20-25.
14. ten Hacken N., Kerstjens H., Postma D. Bronchiectasis. Clin Evid (Online) 2008, 2008:1507.
15. Ilowite J., Spiegler P., Kessler H. Pharmacological treatment options for bronchiectasis. Focus on antimicrobial and anti-inflammatory agents. Drugs 2009, 69(4):407-419.
16. Pappalettera M., Aliberti S., Castellotti P., et al. Bronchiectasis: an update. Clin Respir J 2009, 3:126-134.
17. Goeminne P., Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010, 86:493-501.
18. Metersky M.L. New treatment options for bronchiectasis. Ther Adv Respir Dis 2010, 4:93-99.
19. Redding G.J. Update on treatment of childhood bronchiectasis unrelated to cystic-fibrosis. Paediatr Respir Rev 2011, 12:119-123.
20. Pressler T. Targeting airway inflammation in cystic fibrosis in children: past, present, and future. Paediatr Drugs 2011, 13(3):141-147.
21. Chang A.B. Bronchiectasis: so much yet to learn and to do. Paediatr Respir Rev 2011, 12:89-90.
22. Pasteur M.C., Bilton D., Hill A.T. British Thoracic Society Bronchiectasis (non-CF) Guideline Group: a sub-group of the British Thoracic Society Standards of Care Committee. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 2010, 65:i1-i58.
23. Subie H.A., Fitzgerald D.A. Non-cystic fibrosis bronchiectasis. J Paediatr Child Health 2010, 10.1111/j.1440-1754.2010.01871.x.
24. Elborn J.S., Johnston B., Allen F., et al. Inhaled steroids in patients with bronchiectasis. Respir Med 1992, 86(2):121-124.
25. Tsang K.W., Ho P.L., Lam W.K., et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998, 158(3):723-727.
26. Tsang K.W., Tan K.C., Ho P.L., et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005, 60(3):239-243.
27. Tsang K.W., Lam W.K., Sun J., et al. Regression of bilateral bronchiectasis with inhaled steroid therapy. Respirology 2002, 7(1):77-81.
28. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006, 100:1623-1632.
29. Guran T., Ersu R., Karadag B., et al. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. J Clin Pharm Ther 2008, 33(6):603-611.
30. Kapur N., Bell S., Kolbe J., et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009, 1. CD000996.
31. Holme J., Tomlinson J.W., Stockley R.A., et al. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J 2008, 32(4):1047-1052.
32. Lasserson T., Holt K., Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev 2001, 4. CD002162.
33. Crowley S., Matthews I. Resolution of extensive severe bronchiectasis in an infant. Pediatr Pulmonol 2010, 45(7):717-720.
34. Jaffe A., Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31(6):464-473.
35. Bush A., Rubin B.K. Macrolides as biological response modifiers in cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2003, 24(6):737-748.
36. Giamarellos-Bourboulis E.J. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008, 31:12-20.
37. Crosbie P.A., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33:171-181.
38. Friedlander A.L., Albert R.K. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010, 138(5):1202-1212.
39. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011, 81(1):75-87.
40. Bochet M., Garin N., Janssens J.P., et al. Rev Med Suisse 2011, 7(280):308. 310-312 [in French].
41. Tsang K.W., Ho P.I., Chan K.N., et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13(9):361-364.
42. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105(6):946-949.
43. Mikami M. Nihon Kyobu Shikkan Gakkai Zasshi 1991, 29(1):72-83. [in Japanese].
44. Shibuya Y., Wills P.J., Cole P.J. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Respiration 2001, 68(6):615-619.
45. Gorrini M., Lupi A., Viglio S., et al. Inhibition of human neutrophil elastase by erythromycin and flurythromcyin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001, 25(4):492-499.
46. Koh Y.Y., Lee M.H., Sun Y.H., et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10(5):994-999.
47. Nakamura H., Fujishima S., Inoue T., et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999, 13(6):1371-1379.
48. Yalcin E., Kiper N., Ozcelik U., et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31:49-55.
49. Vila-Justribo M., Dorca-Sargatal J., Bello-Dronda S. Bronchiectasis and macrolides. Arch Bronconeumol 2006, 42(4):205-206.
50. Tsang K.W., Roberts P., Read R.C., et al. The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration. J Antimicrob Chemother 1994, 33(2):289-297.
51. Tagaya E., Tamaoki J., Kondo M., et al. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002, 122(1):213-218.
52. Ohgaki N. Bacterial biofilm in chronic airway infection. Kansenshogaku Zasshi 1994, 68(1):138-151.
53. Davies G., Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004, 59:540-541.
54. Cymbala A.A., Edmonds L.C., Bauer M.A., et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4(2):117-122.
55. Anwar G.A., Bourke S.C., Afolabi G., et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008, 102:1494-1496.
56. Carro L.M. Arch Bronconeumol 2005, 41(5):1-2. [in Spanish].
57. Verleden G.M., Dupont L.J., Vanhaecke J., et al. Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report. J Heart Lung Transplant 2005, 24(8):1155-1158.
58. Corless J.A., Warburton C.J. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2000, 4. CD002174.
59. Llewellyn-Jones C.G., Johnson M.M., Mitchell J.L., et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995, 8(9):1479-1487.
60. Tamaoki J., Chiyotani A., Kobayashi K., et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992, 145(3):548-552.
61. Pizzutto S.J., Upham J.W., Yerkovich S.T., et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2010, 4. CD007525.
62. Inoue H., Aizawa H., Koto H., et al. Effect of cyclooxygenase inhibitor on excessive sputum. Fukuoka Igaku Zasshi 1991, 82(4):177-180.
63. Kapur N., Chang A.B. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007, 4. CD006427.
64. Steele K., Greenstone M., Lasserson J.A. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev 2001, 1. CD002734.
65. Sheikh A., Nolan D., Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev 2001, 4. CD002155.